Document:

Exhibit 10.1

 

FORM OF

GLOBAL POWER EQUIPMENT GROUP INC. 
 RESTRICTED SHARE UNIT AGREEMENT

 

Notice of Restricted Share Unit Award

 

Global Power Equipment Group Inc. (the “Company”) grants to the Grantee named below, in accordance with the terms of the Global Power Equipment Group Inc. 2011 Equity Incentive Plan (the “Plan”) and this Restricted Share Unit Agreement (the “Agreement”), the number of Restricted Share Units set forth below, as of the Date of Grant set forth below.  Capitalized terms used in this Agreement without definition shall have the meanings assigned to them in the Plan.

 

Name of Grantee:

 

	
Date   of Grant:
    	
 
    	
March 31,   2015
    
	
 
    	
 
    	
 
    
	
Number   of Restricted Share Units:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Vesting   Date:
    	
 
    	
June 30,   2016
    

 

Terms of Agreement

 

1.                                      Grant of Restricted Share Units. Subject to and upon the terms, conditions, and restrictions set forth in this Agreement and in the Plan, the Company hereby grants to the Grantee as of the Date of Grant, the Restricted Share Units set forth above. Each Restricted Share Unit shall represent the contingent right to receive one Share and shall at all times be equal in value to one Share. The Restricted Share Units shall be credited in a book entry account established for the Grantee until payment in accordance with Section 2 hereof.

 

2.                                      Vesting and Payment of Restricted Share Units.

 

(a)                                 In General.  Subject to the Grantee’s compliance with the restrictions of Section 7 hereof, or the terms of the Restrictive Covenants Agreement (as defined herein) or of any separately executed covenant not to compete with the Company, as applicable, the number of Restricted Share Units set forth above shall vest on the Vesting Date set forth above, provided that the Grantee shall have remained in the continuous employ of the Company or a Subsidiary through the Vesting Date.  The Company shall deliver to the Grantee the Shares underlying the vested Restricted Share Units within ten (10) days following the Vesting Date.  For purposes of this Section 2, the continuous employment of the Grantee with the Company and its Subsidiaries shall not be deemed to have been interrupted, and the Grantee shall not be deemed to have ceased to be an employee of the Company and its Subsidiaries, by reason of the transfer of his employment among the Company and its Subsidiaries.

 

(b)                                 Involuntary Termination or Termination for Good Reason.  The Restricted Share Units shall immediately vest in full if, prior to the Vesting Date, the Grantee’s employment with the Company or a Subsidiary is terminated (i) by the Company or a Subsidiary without Cause (as defined in Section 22 of this Agreement) or by reason of the Grantee’s Disability (as defined in Section 22 of this Agreement), (ii) by the Grantee for Good Reason (as defined in Section 22 of this Agreement), or (iii) as a result of the Grantee’s death.  Except as otherwise provided in Section 13, the Company shall deliver to the Grantee (or the Grantee’s estate in the event of death) the Shares underlying the vested Restricted Share Units within thirty (30) days following the date of the Grantee’s termination of employment.

 

 

(c)                                  Change of Control.  If a Change of Control occurs while the Grantee is employed by the Company or any Subsidiary and prior to the Vesting Date, then, effective as of the date of such Change of Control, all of the Restricted Share Units shall become fully vested.  Except as otherwise provided in Section 13, the Company shall deliver to the Grantee the Shares underlying such vested Restricted Share Units within thirty (30) days following the date of the Change in Control.

 

3.                                      Forfeiture of Restricted Share Units.

 

(a)                                 Forfeiture of Unvested Awards.  The Restricted Share Units that have not yet vested pursuant to Section 2 (and any right to unpaid Dividend Equivalents under Section 6 with respect to the Restricted Share Units), shall be forfeited automatically without further action or notice if (i) the Grantee ceases to be employed by the Company or a Subsidiary prior to the Vesting Date, except as otherwise provided in Section 2(b) or (ii) the Grantee breaches any of the restrictions of Section 7 hereof, the Restrictive Covenants Agreement (as defined herein) or of any separately executed covenant not to compete with the Company, as applicable.

 

(b)                                 Repayment of Awards.  The Restricted Share Units shall be subject to the provisions of Section 19 of the Plan regarding forfeiture and repayment of awards in the event of (i) termination of the Grantee’s employment for Cause, (ii) the Grantee’s breach of any of the restrictions of Section 7 hereof, the Restrictive Covenants Agreement (as defined herein) or of any separately executed covenant not to compete with the Company, as applicable, or (iii) as provided pursuant to the Company’s Compensation Recovery Policy.  Clause (ii) of the immediately preceding sentence shall be construed as a return of consideration due to your violation of your promises under Section 7 of this Agreement, the Restrictive Covenants Agreement or any separately executed covenant not to compete with the Company, as applicable, and not as a liquidated damages clause.  Nothing contained herein shall eliminate, reduce or compromise (x) the Company’s right to assert that the restrictions provided for in Section 7 of this Agreement, the Restrictive Covenants Agreement or any separately executed covenant not to compete with the Company, as applicable, are fully enforceable as written, or as modified by a court of competent jurisdiction as provided therein, (y) the application of temporary or permanent injunctive relief as a fully appropriate and applicable remedy to enforce the restrictions as provided therein, or (z) the Company’s right to pursue other remedies at law or in equity.  This Section 3(b) shall survive and continue in full force in accordance with its terms and the terms of the Plan notwithstanding any termination of the Grantee’s employment or the payment of the Restricted Share Units as provided herein.

 

4.                                      Transferability.  The Restricted Share Units may not be transferred, assigned, pledged or hypothecated in any manner, or be subject to execution, attachment or similar process, by operation of law or otherwise, unless otherwise provided under the Plan. Any purported transfer or encumbrance in violation of the provisions of this Section 4 shall be void, and the other party to any such purported transaction shall not obtain any rights to or interest in such Restricted Share Units.

 

5.                                      Dividend, Voting and Other Rights.  The Grantee shall not possess any incidents of ownership (including, without limitation, dividend and voting rights) in the Shares underlying the Restricted Share Units until such Shares have been delivered to the Grantee in accordance with Section 2 hereof. The obligations of the Company under this Agreement will be merely that of an unfunded and unsecured promise of the Company to deliver Shares in the future, and the rights of the Grantee will be no greater than that of an unsecured general creditor. No assets of the Company will be held or set aside as security for the obligations of the Company under this Agreement.

 

6.                                      Payment of Dividend Equivalents.  Upon payment of a vested Restricted Share Unit, the Grantee shall be entitled to a cash payment (without interest) equal to the aggregate cash dividends

 

2

 

declared and payable with respect to one (1) Share for each record date that occurs during the period beginning on the Date of Grant and ending on the date the vested Restricted Share Unit is paid (the “Dividend Equivalent”).  The Dividend Equivalents shall be forfeited to the extent that the underlying Restricted Share Unit is forfeited and shall be paid to the Grantee, if at all, at the same time that the related vested Restricted Share Unit is paid to the Grantee in accordance with Section 2.

 

7.                                      Non-Solicitation; Confidentiality; Ownership of Work Product.  In the event that the Grantee is a party to one or more separately executed agreements with the Company, the terms of which restrict (w) the Grantee’s ability to solicit customers of the Company, (x) the Grantee’s ability to solicit employees of the Company, (y) the Grantee’s ability to use or disclose confidential information or trade secrets of the Company, or (z) the ownership of works (collectively, the “Restrictive Covenants Agreement”), then the terms of such applicable restriction or restrictions in the Restrictive Covenants Agreement shall govern in lieu of the corresponding restriction or restrictions set forth in Sections 7(a), 7(b), 7(c) or 7(d) hereof, respectively.  In consideration of, and as a condition to, the Grantee’s employment by the Company, the grant of the Restricted Share Units, a portion of the compensation and other benefits to be paid to the Grantee during such employment, the potential disclosure to the Grantee of Confidential Information (as hereinafter defined) in connection with such employment and other good and valuable consideration, the Grantee and the Company agree as follows:

 

(a)                                 Non-Solicitation of Customers.  During the Grantee’s employment by the Company and for one (1) year after the date the Grantee’s employment ends for any reason (the “Restricted Period”), the Grantee hereby covenants and agrees that the Grantee shall not (in a capacity where the Grantee could use specialized knowledge, training, skill or expertise, Confidential Information (as defined herein), or customer contacts or information obtained from the Company to the detriment of the Company), either directly or indirectly, individually, on behalf of or in concert with others, or as an owner, a shareholder, partner, director, officer, employee, agent or advisor of any business or entity, undertake or engage in any of the following activities without the prior written consent of the Company: solicit, call on or in any manner cause or attempt to cause any Customer (as defined herein) to divert, terminate, limit, modify or fail to enter into any existing or potential business relationship with the Company.  For purposes of this Section 7(a), “Customer” shall mean any customer or client of the Company that (i) the Grantee solicited during the 12-month period prior to termination of the Grantee’s employment with the Company, (ii) the Grantee knows to have done business with the Company during the 12-month period prior to termination of the Grantee’s employment, or (iii) the Grantee had been provided or had access to Confidential Information during the Grantee’s employment with the Company.

 

(b)                                 Non-Solicitation of Employees.  During the Restricted Period, the Grantee hereby covenants and agrees that the Grantee shall not (either directly or indirectly, individually, on behalf of or in concert with others, or as an owner, shareholder, partner, director, officer, employee, agent or advisor of any business or entity) solicit, recruit, induce, entice, endeavor or assist in any effort to cause any person employed by the Company to end such person’s employment with the Company (whether or not such person would commit a breach of contract by accepting such other employment).

 

(c)                                  Confidentiality.

 

(i)                                     The Grantee acknowledges that that in the course of the Grantee’s employment by the Company, the Grantee will be exposed to considerable proprietary, confidential and trade secret information relating to the business and operations of the Company.  The Grantee understands that the Company has expended, and will continue to expend time, money, and effort to develop and maintain its confidential, proprietary and trade secret information which, if misused or disclosed, could be harmful to the Company’s business and could cause the Company to lose its competitive edge in the marketplace.  The Grantee understands that the Company desires to protect its

 

3

 

business and to avoid competition with the Grantee in the event that the Grantee ever leaves the employ of the Company, whether voluntarily or involuntarily.

 

(ii)                                  During the Grantee’s employment by the Company, and after termination of the Grantee’s employment with the Company, for any reason, whether voluntary or involuntary, the Grantee will hold in a fiduciary capacity for the benefit of the Company all information, knowledge or data relating to the Company or any of its businesses which the Company considers to be proprietary, trade secret or confidential that the Grantee obtains or has previously obtained during the Grantee’s employment by the Company and that is not public knowledge (other than as a result of the Grantee’s violation of this provision), including but not limited to the Company’s technology, business plans, business processes, methods of operations, customer information, including contacts, preferences, requirements, pricing, and other customer information, vendor information, financial information, pricing information and strategies, and other business relationships (“Confidential Information”). The Grantee will not directly or indirectly use any Confidential Information for any purpose not associated with the activities of the Company, or communicate, divulge or disseminate Confidential Information to any person or entity not authorized by the Company to receive it at any time during or after the Grantee’s employment with the Company, except with the prior written consent of the Company or as otherwise required by law or legal process.

 

(iii)                               Upon the request of the Company and, in any event, upon the termination of the Grantee’s employment with the Company, the Grantee shall deliver to the Company all property in the Grantee’s possession or control belonging to the Company, including but not limited to all keys, computers, credit cards, telephones, office equipment, software, and all Confidential Information of the Company.  The Grantee shall return all such information, including all memoranda, notes, records, manuals, files or other documents in any form whatsoever (including information contained in computer or other electronic memory or on any computer or electronic storage device), including all copies, pertaining to the performance of the Grantee’s services for the Company, the business of the Company, whether made or compiled by the Grantee or provided to or obtained by the Grantee at any time during the Grantee’s employment with the Company.  If the Company requests, the Grantee agrees to provide written confirmation that the Grantee has returned all such materials consistent with this provision.

 

(iv)                              The restrictions stated in this Section 7 are in addition to and not in lieu of protections afforded to trade secrets and confidential information under Applicable Laws.   Nothing in this Agreement is intended to or shall be interpreted as diminishing or otherwise limiting the Company’s right under Applicable Laws to protect its trade secrets and confidential information.

 

(d)                                 Ownership of Work Product.

 

(i)                                     The Company shall own all Work Product (as defined herein).  All Work Product shall be considered work made for hire by the Grantee and owned by the Company.  The Grantee hereby irrevocably relinquishes for the benefit of the Company any moral rights in and to the Work Product recognized by Applicable Law.  If any of the Work Product may not, by operation of law, be considered work made for hire by the Grantee for the Company, or if ownership of all right, title, and interest in and to the intellectual property rights therein shall not otherwise vest exclusively in the Company, the Grantee hereby agrees to assign, and upon creation thereof automatically assigns, without further consideration, the ownership of all trade secrets, registered and unregistered copyrights under United States and international law, copyrightable material or works, patents, patentable inventions and other intellectual property rights therein to the Company, its successors and assigns.  The Company shall have the right to obtain and hold in its own name copyright registrations, trademark registrations, patents and any other protection available in the foregoing.

 

4

 

(ii)                                  The Grantee agrees to perform, upon the reasonable request of the Company, during or after employment such further acts as may be necessary or desirable to transfer, perfect, and defend the Company’s ownership of the Work Product, including but not limited to: (A) executing, acknowledging, and delivering any requested affidavits and documents of assignment and conveyance; (B) assisting in the preparation, prosecution, procurement, maintenance and enforcement of all copyrights and, if applicable, patents with respect to the Work Product in any countries; (C) providing testimony in connection with any proceeding affecting the right, title, or interest of the Company in any Work Product; and (D) performing any other acts deemed necessary or desirable to carry out the purposes of this Agreement.  The Company shall reimburse any reasonable out-of-pocket expenses incurred by the Grantee at the Company’s request in connection with the foregoing, including (unless the Grantee is otherwise being compensated at the time) a reasonable and pre-agreed per diem or hourly fee for services rendered following termination of the Grantee’s employment.

 

(iii)                               For purposes of this Section 7, “Work Product” means all intellectual property rights including all trade secrets, registered and unregistered copyrights under U.S. and international law, copyrightable material or works, patents, patentable inventions, discoveries and improvements, and other intellectual property rights, in any technology software, data files documentation, or other work product that relates to the business and interests of the Company and that the Grantee conceives, develops, creates or delivers to the Company at any time during the Grantee’s employment with the Company.

 

(e)                                  Miscellaneous.

 

(i)                                     The Grantee acknowledges that the restrictions, prohibitions and other provisions in this Section 7 are reasonable, fair and equitable in scope, terms and duration, and are necessary to protect the legitimate business interests of the Company.  The terms and provisions of this Section 7 are intended to be separate and divisible provisions and if, for any reason, any one or more of them is held to be invalid or unenforceable, neither the validity nor the enforceability of any other provision of this Agreement shall thereby be affected.  It is the intention of the parties to this Agreement that the potential restrictions on the Grantee imposed by Sections 7(a) and (b) be reasonable in scope and in all other respects.  If for any reason any court of competent jurisdiction shall find any provisions of this Section 7 unreasonable in scope or otherwise, the Grantee and the Company agree that the restrictions and prohibitions contained herein may be modified by a court of competent jurisdiction and shall be effective to the fullest extent allowed under Applicable Law in such jurisdiction.  The Grantee agrees to disclose the existence of this Agreement to any subsequent employer.

 

(ii)                                  The Grantee hereby agrees that any remedy at law for any breach or threatened breach of the provisions of this Section 7 will be inadequate and that the Company will be entitled to injunctive relief in addition to any other remedy the Company might have under this Agreement.  The Grantee hereby expressly acknowledges that the harm which might result to the Company’s business as a result of any noncompliance by the Grantee with the provisions of this Section 7 would be largely irreparable.  The parties agree that if the Company pursues legal action to enforce the terms and conditions of this Section 7 and obtains all or part of the relief sought, the Grantee shall be responsible for the reasonable attorney’s fees and costs of the Company in bringing such action.

 

(iii)                               Notwithstanding any other provision of this Agreement or the Plan, the rights and obligations of the parties hereto, and any claims or disputes relating to this Section 7 shall be governed by and construed in accordance with the laws of the State of Texas without giving effect to the principles of conflict of laws thereof.  Each party agrees that any action arising out of or relating to this Section 7 shall be brought exclusively in the state courts located in Dallas County, Texas and the United States District Court for the Northern District of Texas (Dallas Division), accepts for itself and in respect

 

5

 

of its property, generally and unconditionally, the jurisdiction of those courts, and irrevocably waives any objection, including, without limitation, any objection to the laying of venue or based on the grounds of forum non conveniens, which it may now or hereafter have to the bringing of any action in those jurisdictions.

 

(iv)                              For purposes of this Section 7, the term “Company” shall be deemed to include Global Power Equipment Group Inc., its Subsidiaries and affiliates, and all of their respective successors and assigns.

 

8.                                      No Employment Contract.  Nothing contained in this Agreement shall confer upon the Grantee any right with respect to continuance of employment by the Company and its Subsidiaries, nor limit or affect in any manner the right of the Company and its Subsidiaries to terminate the employment or adjust the compensation of the Grantee, in each case with or without Cause.

 

9.                                      Relation to Other Benefits.  Any economic or other benefit to the Grantee under this Agreement or the Plan shall not be taken into account in determining any benefits to which the Grantee may be entitled under any profit-sharing, retirement or other benefit or compensation plan maintained by the Company or a Subsidiary and shall not affect the amount of any life insurance coverage available to any beneficiary under any life insurance plan covering employees of the Company or a Subsidiary.

 

10.                               Taxes and Withholding.  The Grantee is responsible for any federal, state, local or other taxes with respect to the Restricted Share Units and the Dividend Equivalents.  The Company does not guarantee any particular tax treatment or results in connection with the grant or vesting of the Restricted Share Units, the delivery of Shares or the payment of Dividend Equivalents.  To the extent the Company or any Subsidiary is required to withhold any federal, state, local, foreign or other taxes in connection with the delivery of Shares under this Agreement, then, except as otherwise provided below, the Company or Subsidiary (as applicable) shall retain a number of Shares otherwise deliverable hereunder with a value equal to the required withholding (based on the Fair Market Value of the Shares on the date of delivery); provided that in no event shall the value of the Shares retained exceed the minimum amount of taxes required to be withheld or such other amount that will not result in a negative accounting impact. Notwithstanding the preceding sentence, the Grantee may elect, on a form provided by the Company and subject to any terms and conditions imposed by the Company, to pay or provide for payment of the required tax withholding.  If the Company or any Subsidiary is required to withhold any federal, state, local or other taxes at any time other than upon delivery of the Shares under this Agreement, then the Company or Subsidiary (as applicable) shall have the right in its sole discretion to (a) require the Grantee to pay or provide for payment of the required tax withholding, or (b) deduct the required tax withholding from any amount of salary, bonus, incentive compensation or other amounts otherwise payable in cash to the Grantee (other than deferred compensation subject to Section 409A of the Code).   If the Company or any Subsidiary is required to withhold any federal, state, local or other taxes with respect to Dividend Equivalents, then the Company or Subsidiary (as applicable) shall have the right in its sole discretion to reduce the cash payment related to the Dividend Equivalent by the applicable tax withholding.

 

11.                               Adjustments.  The number and kind of shares of stock deliverable pursuant to the Restricted Share Units are subject to adjustment as provided in Section 15 of the Plan.

 

12.                               Compliance with Law.  The Company shall make reasonable efforts to comply with all applicable federal and state securities laws and listing requirements with respect to the Restricted Share Units; provided that, notwithstanding any other provision of this Agreement, and only to the extent permitted under Section 409A of the Code, the Company shall not be obligated to deliver any Shares pursuant to this Agreement if the delivery thereof would result in a violation of any such law or listing requirement.

 

6

 

13.                               Section 409A of the Code.  It is intended that the Restricted Share Units and any Dividend Equivalents provided pursuant to this Agreement shall be exempt from, or comply with, the requirements of Section 409A of the Code, and this Agreement shall be interpreted, administered and governed in accordance with such intent.  To the extent necessary to give effect to such intent, the Grantee’s termination of employment shall mean, for purposes of this Agreement, the Grantee’s “separation from service” within the meaning of Section 409A of the Code.  In particular, it is intended that the Restricted Share Units and any Dividend Equivalents shall be exempt from Section 409A of the Code, to the maximum extent possible, pursuant to the “short-term deferral” exception thereto.  However, to the extent that the Restricted Share Units or any Dividend Equivalents constitute a deferral of compensation subject to the requirements of Section 409A of the Code (for example, because the Grantee’s governing employment agreement defines “Good Reason” in a manner such that the Grantee’s termination of employment for Good Reason would not be treated as an involuntary separation from service for purposes of Section 409A of the Code), then the following rules shall apply, notwithstanding any other provision of this Agreement to the contrary:

 

(a)                                 The Company will deliver the Shares underlying any Restricted Share Units that become vested in accordance with Section 2(b) or 2(c) of this Award Agreement and pay any Dividend Equivalents with respect to those vested Restricted Share Units within thirty (30) days after the first to occur of (i) the Vesting Date for the Restricted Share Units; (ii) the occurrence of a Change of Control that is also a “change in the ownership,” a “change in the effective control,” or a “change in the ownership of a substantial portion of the assets” of the Company within the meaning of Section 409A of the Code; or (iii) the Grantee’s “separation from service” within the meaning of Section 409A of the Code; and

 

(b)                                 If the Restricted Share Units (and any related Dividend Equivalents) become payable as a result of the Grantee’s separation from service (other than as a result of the Grantee’s death) and the Grantee is a “specified employee” at that time within the meaning of Section 409A of the Code (as determined pursuant to the Company’s policy for identifying specified employees), the Company will deliver the Shares underlying the vested Restricted Share Units and pay any related Dividend Equivalents to the Grantee on the first business day that is at least six months after the date of the Grantee’s separation from service (or upon the Grantee’s death if the Grantee dies before the end of that six-month period).

 

14.                               Amendments.  Subject to the terms of the Plan, the Committee may modify this Agreement upon written notice to the Grantee. Any amendment to the Plan shall be deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto.  Notwithstanding the foregoing, no amendment of the Plan or this Agreement shall adversely affect in a material way the rights of the Grantee under this Agreement without the Grantee’s consent unless the Committee determines, in good faith, that such amendment is required for the Agreement to either be exempt from the application of, or comply with, the requirements of Section 409A of the Code, or as otherwise may be provided in the Plan.

 

15.                               Severability.  In the event that one or more of the provisions of this Agreement shall be invalidated for any reason by a court of competent jurisdiction, any provision so invalidated shall be deemed to be separable from the other provisions hereof, and the remaining provisions hereof shall continue to be valid and fully enforceable.

 

16.                               Relation to Plan.  This Agreement is subject to the terms and conditions of the Plan. Except with respect to the provisions of the Restrictive Covenants Agreement and of any separately executed covenant not to compete with the Company expressly referenced herein, this Agreement and the Plan contain the entire agreement and understanding of the parties with respect to the subject matter

 

7

 

contained in this Agreement, and supersede all prior written or oral communications, representations and negotiations in respect thereto. Except as otherwise provided in Section 7(e)(iii) hereof, in the event of any inconsistency between the provisions of this Agreement and the Plan, the Plan shall govern.  The Committee acting pursuant to the Plan, as constituted from time to time, shall, except as expressly provided otherwise herein, have the right to determine any questions that arise in connection with the grant of the Restricted Share Units.

 

17.                               Successors and Assigns.  Without limiting Section 4, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of the Grantee, and the successors and assigns of the Company.

 

18.                               Governing Law.  Except as otherwise provided in Section 7 hereof, the interpretation, performance, and enforcement of this Agreement shall be governed by the laws of the State of Delaware, without giving effect to the principles of conflict of laws thereof.

 

19.                               Use of Grantee’s Information.  Information about the Grantee and the Grantee’s participation in the Plan may be collected, recorded and held, used and disclosed for any purpose related to the administration of the Plan. The Grantee understands that such processing of this information may need to be carried out by the Company and its Subsidiaries and by third-party administrators whether such persons are located within the Grantee’s country or elsewhere, including the United States of America. The Grantee consents to the processing of information relating to the Grantee and the Grantee’s participation in the Plan in any one or more of the ways referred to above.

 

20.                               Electronic Delivery.  The Grantee hereby consents and agrees to electronic delivery of any documents that the Company may elect to deliver (including, but not limited to, prospectuses, prospectus supplements, grant or award notifications and agreements, account statements, annual and quarterly reports, and all other forms of communications) in connection with this and any other award made or offered under the Plan. The Grantee understands that, unless earlier revoked by the Grantee by giving written notice to the VP of Human Resources of the Company, this consent shall be effective for the duration of the Agreement. The Grantee also understands that he or she shall have the right at any time to request that the Company deliver written copies of any and all materials referred to above at no charge. The Grantee hereby consents to any and all procedures the Company has established or may establish for an electronic signature system for delivery and acceptance of any such documents that the Company may elect to deliver, and agrees that his or her electronic signature is the same as, and shall have the same force and effect as, his or her manual signature. The Grantee consents and agrees that any such procedures and delivery may be effected by a third party engaged by the Company to provide administrative services related to the Plan.

 

21.                               No Fractional Shares.   Fractional Shares or units will be subject to rounding conventions adopted by the Company from time to time; provided that in no event will the total shares issued exceed the total units granted under this award.

 

22.                               Definitions.  As used in this Agreement, the following definitions shall apply.

 

(a)                                 Cause shall have the meaning assigned such term, if any, (i) in the employment, letter or severance agreement, if any, between the Grantee and the Company or a Subsidiary, or (ii) if none, under a severance plan or arrangement maintained by the Company or a Subsidiary that applies to the Grantee on the date of termination. If the Grantee is not a party to an employment, letter or severance agreement with the Company or a Subsidiary in which such term is defined or if during the applicable severance protection period, the Grantee is not a participant in any severance plan or arrangement maintained by the Company or a Subsidiary, then “Cause” has the meaning given such term in the Plan.

 

8

 

(b)                                 Disability has the meaning set forth in the long-term disability plan of the Company or a Subsidiary applicable to the Grantee.

 

(c)                                  Good Reason shall have the meaning assigned such term, if any, (i) in the employment, letter or severance agreement, if any, between the Grantee and the Company or a Subsidiary, or (ii) if none, under a severance plan or arrangement maintained by the Company or a Subsidiary that applies to the Grantee on the date of termination. If the Grantee is not a party to an employment, letter or severance agreement with the Company or a Subsidiary in which such term is defined or if during the applicable severance protection period, the Grantee is not a participant in any severance plan or arrangement maintained by the Company or a Subsidiary, then “Good Reason” means a reduction by the Company of Grantee’s annual base salary by more than 10% (other than an across-the-board reduction which applies in a comparable manner to other senior executives of the Company); provided, however, that the Grantee provides notice to the Company of the existence of the condition constituting Good Reason within 90 days after the initial existence of such condition and the Company fails to remedy such condition within 30 days after the receipt of such notice from the Grantee.

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Date of Grant.

 

 

	
 
    	
GLOBAL POWER EQUIPMENT GROUP INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name: 
    	
Terrence J. Cryan
    
	
 
    	
Title: 
    	
President and CEO
    
				

 

 

By executing this Agreement, you acknowledge that a copy of the Plan, Plan Summary and Prospectus, and the Company’s most recent Annual Report and Proxy Statement (the “Prospectus Information”) either have been received by you or are available for viewing on the Company’s internet site at www.globalpower.com, and you consent to receiving this Prospectus Information electronically, or, in the alternative, agree to contact Keri Jolly at 214-574-2733, to request a paper copy of the Prospectus Information at no charge.

 

 

	
 
    	
GRANTEE
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name:
    	
 
    

 

9Exhibit 10.1

 

To subscribe for Units including Preferred
Stock and Warrants 

to Purchase Shares of Common Stock in the
private offering of

 

PROTEA BIOSCIENCES GROUP, INC.

 

		1.	Date and Fill in the number of units (each unit consisting of (a) 50,000 shares of Series
A Convertible Preferred Stock, par value $0.0001 per share, of the Company (“Preferred Stock”), and (b)
a warrant to purchase 200,000 shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”)
at an exercise price of $0.375 per share for a period of 3 years following the Final Closing Date (as such term is defined in the
Warrant) (the “Warrant”) (the “Warrant” and together with the Preferred Stock, the “Units”)
being subscribed for and Complete and Sign the Signature Page included in this Subscription Agreement.

 

		2.	Initial the Accredited Investor Certification attached to this Subscription Agreement.

 

		3.	Complete and Sign the Signature Page attached to this Subscription Agreement. NOTICE:
Please note that by executing the attached Subscription Agreement, you will be deemed to have executed the Unit Purchase Agreement
(Exhibit B to the Memorandum), the Registration Rights Agreement (Exhibit C to the Memorandum), and the Warrant (Exhibit B to the
Unit Purchase Agreement) (collectively the “Transaction Documents”), each of which are attached to the Memorandum,
and will be treated for all purposes as if you did sign each such Transaction Document even though you may not have physically
signed the signature pages to such documents.

 

		4.	Complete and Return the attached Investor Questionnaire and, if applicable, Wire Transfer
Authorization attached to this Subscription Agreement.

 

		5.	Return all forms to your Account Executive and then send all signed original documents with
a check (if applicable) to:

 

Laidlaw & Company (UK) Ltd.

546 Fifth Avenue, 5th Floor

New York, NY 10036

 

		6.	Please make your subscription payment
                                         payable to the order of “Signature Bank, as Escrow Agent for Protea Biosciences
                                         Group, Inc.” Account No. 1502351989

 

For
wiring funds directly to the escrow account, use the following instructions:

 

	 	Signature Bank
	 	261 Madison Avenue
	 	New York, NY 10016
	 	Acct. Name:	Signature Bank as Escrow Agent for 
	 	 	Protea Biosciences Group, Inc.
	 	ABA Number:	026013576
	 	SWIFT Code:	SIGNUS33
	 	A/C Number:	1502351989
	 	 	 
	 	FBO:	Purchaser Name 
	 	 	Social Security Number
	 	 	Address

 

    	1

    	 

    

 

ALL SUBSCRIPTION DOCUMENTS MUST BE FILLED
IN AND SIGNED EXACTLY AS SET FORTH WITHIN.

 

SUBSCRIPTION AGREEMENT

 

FOR

 

PROTEA BIOSCIENCES GROUP, INC.

 

Protea Biosciences Group, Inc.

c/o Laidlaw & Company (UK) Ltd.

546 Fifth Avenue, 5th Floor

New York, NY 10036

 

Ladies and Gentlemen:

 

1. Subscription.
The undersigned (the “Purchaser”) will purchase the number of units (“Units”)
of securities of Protea Biosciences Group, Inc., a Delaware corporation (the “Company”), set forth on
the signature page to this Subscription Agreement, at a purchase price of $100,000 per Unit, with each Unit consisting of a) 50,000
shares of Series A Convertible Preferred Stock, par value $0.0001 per share, of the Company (“Preferred Stock”),
and (b) a warrant to purchase 200,000 shares of common stock, par value $0.0001 per share, of the Company (“Common
Stock”) at an exercise price of $0.375 per share for a period of 3 years following the Final Closing Date (as such
term is defined in the Warrant) (the “Warrant”). The shares of Common Stock underlying the Warrant may
hereinafter be referred to as the “Warrant Shares”).The shares of Common Stock underlying the Preferred
Stock may hereinafter be referred to as the “Conversion Shares”). The Units are being offered (the “Offering”)
by the Company pursuant to the offering terms set forth in the Company’s Confidential Private Placement Memorandum,
dated September 2, 2014, as may be amended and/or supplemented, from time to time (collectively, the “Memorandum”).

 

The Units are being offered
on a “reasonable efforts, all or none” basis with respect to the minimum of $2,000,000 (the “Minimum
Offering Amount”), which shall be exclusive of the Conversion Amount (defined below) and thereafter on a “reasonable
efforts” basis up to the maximum of $7,000,000 (the “Maximum Offering Amount”); provided that
Laidlaw & Company (UK) Ltd. (“Laidlaw” or “Placement Agent”) may, in its
sole discretion, sell up to an additional $2,000,000 in Units to cover over-subscriptions (the “Over-Allotment”)
which amounts shall be exclusive of the Maximum Offering Amount. In addition, the Maximum Offering Amount and Over-Allotment shall
not include (i) up to an additional $2,000,000 (the “Conversion Amount”) in Units issuable to the holders
of Convertible Promissory Notes (the “Notes”) that are convertible into Units issued in this Offering
upon the first Closing (defined below) of the Offering and (ii) up to an additional $1,000,000, plus, if and as applicable, accrued
unpaid interest (the “Additional Convertible Loan Amount”) in Units that may be issued
to holders in connection with the conversion of outstanding Notes upon the Initial Closing of the Offering and/or such other investors
as the Company and the Placement Agent may mutually agree upon (collectively, the “Additional Investors”).

 

    	2

    	 

    

 

The Units may be sold at
one or more closings of the Offering (each a “Closing”, and, collectively, the “Closings”),
at any time during the Offering Period (defined hereafter); provided, however, that no Closing may be effectuated unless and until
irrevocable subscriptions for at least the Minimum Offering Amount, which amount shall include any Units sold to Company Investors,
have been deposited in the Escrow Account (defined hereafter). The minimum investment amount that may be purchased by an investor
is one Unit at a price of $100,000 (the “Investor Minimum Investment”); provided however, the Company
and Laidlaw, in their mutual discretion, may accept an investor subscription for an amount less than the Investor Minimum Investment.
The subscription for the Units will be made in accordance with and subject to the terms and conditions of this Subscription Agreement
and the Memorandum.

 

All subscription funds
will be held in a non-interest bearing escrow account in the Company’s name at Signature Bank (the “Escrow Agent”),
261 Madison Avenue, New York, New York 10016, or with such other escrow agent as may be appointed by Laidlaw and the Company (the
“Escrow Account”).

 

The Units will be offered
for a period commencing on the date of the Memorandum and continue until the earliest of (i) October 15, 2014 if the Minimum Offering
Amount has not been raised,which period may be extended by the Company and Laidlaw in their joint discretion, without notice to
or consent by prospective investors until October 31, 2014 (collectively, the “Minimum Offering Amount Deadline”)
or (ii) the sale of the Maximum Offering Amount unless Placement Agent exercises the Greenshoe, or (iii) October 31, 2014 (the
“Termination Date”), for a period commencing on the date of the Memorandum (the “Initial
Offering Period”), which period may be extended by the Company and Laidlaw in their joint discretion, without notice
to or consent by prospective investors, until December 31, 2014 (the “Final Termination Date”) if the
Minimum Offering Amount has not be subscribed by the Minimum Offering Amount Deadline. This additional period, together with the
Initial Offering Period, shall be referred to herein as the “Offering Period”. In
the event that (i) subscriptions for the Offering are rejected in whole (at the sole discretion of the Company),
or (ii) the Minimum Offering Amount has been subscribed for prior to October 15, 2014, or, if extended, prior to October
31, 2014, or (iii) the Offering is otherwise terminated by the Company or the Placement Agent prior to the expiration of the Initial
Offering Period or, if extended, prior to the Final Termination Date, then the Escrow Agent will refund all subscription funds
held in the Escrow Account to the persons who submitted such funds, without interest, penalty or deduction. If a subscription is
rejected in part (at the sole discretion of the Company or Laidlaw) and the Company accepts the portion not so rejected, the funds
for the rejected portion of such subscription will be returned without interest, penalty, expense or deduction.

 

Laidlaw and the Company
each reserves the right (but is not obligated) to have its Employees, agents, officers, directors and affiliates of Laidlaw or
the Company may purchase Units in the Offering and all such purchases will be counted towards the Minimum Offering Amount and the
Maximum Offering Amount.

 

The terms of the Offering
are more completely described in the Memorandum and such terms are incorporated herein in their entirety. Certain capitalized terms
used, but not otherwise defined herein, will have the respective meanings provided in the Memorandum.

 

2.          Payment.
The Purchaser encloses herewith a check payable to, or will immediately make a wire transfer payment to, “Signature
Bank, as Escrow Agent for Protea Biosciences Group, Inc.,” in the full amount of the purchase price of the Units being
subscribed for. Together with the check for, or wire transfer of, the full purchase price, the Purchaser is delivering a completed
and executed Signature Page to this Subscription Agreement along with a completed and executed Investor Questionnaire, which is
attached hereto as Exhibit A. By executing this Subscription Agreement (this “Subscription Agreement”),
you will be deemed to have executed each of the Unit Purchase Agreement in the form of Exhibit B to the Memorandum (the “UPA”),
the Registration Rights Agreement in the form of Exhibit C to the Memorandum, and the Warrant in the form of Exhibit B to the
Unit Purchase Agreement (collectively the “Transaction Documents”), and
will be bound by the respective terms of each of them.

 

    	3

    	 

    

 

3.          Deposit
of Funds. All payments made as provided in Section 2 hereof will be deposited by the Purchaser as soon as practicable
with the Escrow Agent, or such other escrow agent appointed by Laidlaw and the Company, in the Escrow Account. In the event that
the Company does not effect a Closing during the Offering Period, the Escrow Agent will refund all subscription funds, without
deduction and/or interest accrued thereon, and will return the subscription documents to each Purchaser. If the Company or Laidlaw
rejects a subscription, either in whole or in part (at the sole discretion of the Company or Laidlaw), the rejected subscription
funds or the rejected portion thereof will be returned promptly to such Purchaser without interest, penalty, expense or deduction.

 

4.          Acceptance
of Subscription. The Purchaser understands and agrees that the Company or Laidlaw, each in its sole discretion, reserves the
right to accept this or any other subscription for the Units, in whole or in part, notwithstanding prior receipt by the Purchaser
of notice of acceptance of this or any other subscription. The Company will have no obligation hereunder until the Company executes
an executed copy of the Subscription Agreement. If Purchaser’s subscription is rejected in whole (at the sole discretion
of the Company or Laidlaw), the Offering is terminated or the Minimum Offering Amount is not subscribed for and accepted prior
to the expiration of the Initial Offering Period or, if extended, prior to the Final Termination Date, all funds received from
the Purchaser will be returned without interest, penalty, expense or deduction, and this Subscription Agreement will thereafter
be of no further force or effect. If Purchaser’s subscription is rejected in part (at the sole discretion of the Company
or Laidlaw) and the Company accepts the portion not so rejected, the funds for the rejected portion of such subscription will be
returned without interest, penalty, expense or deduction, and this Subscription Agreement will continue in full force and effect
to the extent such subscription was accepted.

 

5.          Representations
and Warranties of the Purchaser. The Purchaser hereby acknowledges, represents, warrants, and agrees as follows:

 

(a)          None
of the Preferred Stock, the Warrants, the Conversion Shares, or the Warrant Shares (collectively referred to hereafter as the “Securities”)
are registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities
laws. The Purchaser understands that the offering and sale of the Securities is intended to be exempt from registration under the
Securities Act, by virtue of Section 4(a)(2) thereof and the provisions of Regulation D promulgated thereunder, based, in part,
upon the representations, warranties and agreements of the Purchaser contained in this Subscription Agreement and the Unit Purchase
Agreement;

 

(b)          The
Purchaser and the Purchaser’s attorney, accountant, purchaser representative and/or tax advisor, if any (collectively, “Advisors”),
have received and have carefully reviewed the Memorandum, this Subscription Agreement, and each of the Transaction Documents and
all other documents requested by the Purchaser or its Advisors, if any, and understand the information contained therein, prior
to the execution of this Subscription Agreement;

 

(c)          Neither
the Securities and Exchange Commission (the “Commission”) nor any state securities commission has approved
or disapproved of the Securities or passed upon or endorsed the merits of the Offering or confirmed the accuracy or determined
the adequacy of the Memorandum. The Memorandum has not been reviewed by any Federal, state or other regulatory authority. Any representation
to the contrary may be a criminal offense;

 

    	4

    	 

    

 

(d)          All
documents, records, and books pertaining to the investment in the Securities including, but not limited to, all information regarding
the Company and the Securities, have been made available for inspection and reviewed by the Purchaser and its Advisors, if any;

 

(e)          The
Purchaser and its Advisors, if any, have had a reasonable opportunity to ask questions of and receive answers from the Company’s
officers and any other persons authorized by the Company to answer such questions, concerning, among other related matters, the
Offering, the Securities, the Transaction Documents and the business, financial condition, results of operations and prospects
of the Company and all such questions have been answered by the Company to the full satisfaction of the Purchaser and its Advisors,
if any;

 

(f)          In
evaluating the suitability of an investment in the Company, the Purchaser has not relied upon any representation or other information
(oral or written) other than as stated in the Memorandum;

 

(g)          The
Purchaser is unaware of, is in no way relying on, and did not become aware of the offering of the Securities through or as a result
of, any form of general solicitation or general advertising including, without limitation, any article, notice, advertisement or
other communication published in any newspaper, magazine or similar media or broadcast over television, radio or over the Internet,
in connection with the offering and sale of the Securities and is not subscribing for the Securities and did not become aware of
the Offering through or as a result of any seminar or meeting to which the Purchaser was invited by, or any solicitation of a subscription
by, a person not previously known to the Purchaser in connection with investments in securities generally;

 

(h)          The
Purchaser has taken no action which would give rise to any claim by any person for brokerage commissions, finders’ fees or
the like relating to this Subscription Agreement or the transactions contemplated hereby (other than fees to be paid by the Company
to Laidlaw, as described in the Memorandum);

 

(i)          The
Purchaser, either alone or together with its Advisors, if any, has such knowledge and experience in financial, tax, and business
matters, and, in particular, investments in securities, so as to enable it to utilize the information made available to it in connection
with the Offering to evaluate the merits and risks of an investment in the Securities and the Company and to make an informed investment
decision with respect thereto;

 

(j)          The
Purchaser is not relying on the Company, Laidlaw or any of their respective employees or agents with respect to the legal, tax,
economic and related considerations of an investment in any of the Securities and the Purchaser has relied on the advice of, or
has consulted with, only its own Advisors;

 

(k)          The
Purchaser is acquiring the Securities solely for such Purchaser’s own account for investment and not with a view to resale
or distribution thereof, in whole or in part. The Purchaser has no agreement or arrangement, formal or informal, with any person
to sell or transfer all or any part of any of the Securities and the Purchaser has no plans to enter into any such agreement or
arrangement;

 

(l)          The
Purchaser understands and agrees that purchase of the Securities is a high risk investment and the Purchaser is able to afford
an investment in a speculative venture having the risks and objectives of the Company. The Purchaser must bear the substantial
economic risks of the investment in the Securities indefinitely because none of the Securities may be sold, hypothecated or otherwise
disposed of unless subsequently registered under the Securities Act and applicable state securities laws or an exemption from such
registration is available. Legends will be placed on the certificates representing the Common Stock, the Warrants and the shares
of Common Stock issuable upon exercise of the Warrants to the effect that such securities have not been registered under the Securities
Act or applicable state securities laws and appropriate notations thereof will be made in the Company’s books;

 

    	5

    	 

    

 

(m)          The
Purchaser has adequate means of providing for such Purchaser’s current financial needs and foreseeable contingencies and
has no need for liquidity from its investment in the Securities for an indefinite period of time;

 

(n)          The
Purchaser is aware that an investment in the Securities involves a number of very significant risks and has carefully read and
considered the matters set forth in the Memorandum and, in particular, the matters under the caption “Risk Factors”
therein and understands any of such risk may materially adversely affect the Company’s operations and future prospects;

 

(o)          The
Purchaser is an “accredited investor” within the meaning of Regulation D, Rule 501(a), promulgated by the Securities
and Exchange Commission under the Securities Act and has truthfully and accurately completed the Investor Questionnaire attached
as Exhibit A to this Subscription Agreement and will submit to the Company such further assurances of such status as may
be reasonably requested by the Company;

 

(p)          The
Purchaser: (i) if a natural person, represents that the Purchaser has reached the age of 21 and has full power and authority to
execute and deliver this Subscription Agreement and all other related agreements or certificates and to carry out the provisions
hereof and thereof; (ii) if a corporation, partnership, or limited liability company, or association, joint stock company, trust,
unincorporated organization or other entity, represents that such entity was not formed for the specific purpose of acquiring the
Securities, such entity is duly organized, validly existing and in good standing under the laws of the state of its organization,
the consummation of the transactions contemplated hereby is authorized by, and will not result in a violation of state law or its
charter or other organizational documents, such entity has full power and authority to execute and deliver this Subscription Agreement
and all other related agreements or certificates and to carry out the provisions hereof and thereof and to purchase and hold the
Securities, the execution and delivery of this Subscription Agreement has been duly authorized by all necessary action, this Subscription
Agreement has been duly executed and delivered on behalf of such entity and is a legal, valid and binding obligation of such entity;
or (iii) if executing this Subscription Agreement in a representative or fiduciary capacity, represents that it has full power
and authority to execute and deliver this Subscription Agreement in such capacity and on behalf of the subscribing individual,
ward, partnership, trust, estate, corporation, or limited liability company or partnership, or other entity for whom the Purchaser
is executing this Subscription Agreement, and such individual, partnership, ward, trust, estate, corporation, or limited liability
company or partnership, or other entity has full right and power to perform pursuant to this Subscription Agreement and make an
investment in the Company, and represents that this Subscription Agreement constitutes a legal, valid and binding obligation of
such entity. The execution and delivery of this Subscription Agreement will not violate or be in conflict with any order, judgment,
injunction, agreement or controlling document to which the Purchaser is a party or by which it is bound;

 

(q)          The
Purchaser and its Advisors, if any, have had the opportunity to obtain any additional information, to the extent the Company had
such information in its possession or could acquire it without unreasonable effort or expense, necessary to verify the accuracy
of the information contained in the Memorandum including, but not limited to, the terms and conditions of the Securities as set
forth therein and the Transaction Documents and all other related documents, received or reviewed in connection with the purchase
of the Securities and have had the opportunity to have representatives of the Company provide them with such additional information
regarding the terms and conditions of this particular investment and the financial condition, results of operations, business and
prospects of the Company deemed relevant by the Purchaser or its Advisors, if any, and all such requested information, to the extent
the Company had such information in its possession or could acquire it without unreasonable effort or expense, has been provided
by the Company in writing to the full satisfaction of the Purchaser and its Advisors, if any;

 

    	6

    	 

    

 

(r)          The
Purchaser represents to the Company that any information which the undersigned has heretofore furnished or is furnishing herewith
to the Company is complete and accurate and may be relied upon by the Company in determining the availability of an exemption from
registration under Federal and state securities laws in connection with the offering of securities as described in the Memorandum;

 

(s)          The
Purchaser has significant prior investment experience, including investment in non-listed and unregistered securities. The Purchaser
has a sufficient net worth to sustain a loss of its entire investment in the Company in the event such a loss should occur. The
Purchaser’s overall commitment to investments which are not readily marketable is not excessive in view of the Purchaser’s
net worth and financial circumstances and the purchase of the Securities will not cause such commitment to become excessive. This
investment is a suitable one for the Purchaser;

 

(t)          The
Purchaser is satisfied that it has received adequate information with respect to all matters which it or its Advisors, if any,
consider material to its decision to make this investment;

 

(u)          The
Purchaser acknowledges that any and all estimates or forward-looking statements or projections included in the Memorandum were
prepared by the Company in good faith, but that the attainment of any such projections, estimates or forward-looking statements
cannot be guaranteed, will not be updated by the Company and should not be relied upon;

 

(v)         No
oral or written representations have been made, or oral or written information furnished, to the Purchaser or its Advisors, if
any, in connection with the offering of the Securities which are in any way inconsistent with the information contained in the
Memorandum;

 

(w)          Within
five (5) days after receipt of a request from the Company, the Purchaser will provide such information and deliver such documents
as may reasonably be necessary to comply with any and all laws and ordinances to which the Company is subject;

 

(x)          THE
SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF CERTAIN STATES AND ARE BEING
OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE SECURITIES ARE SUBJECT
TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER SAID ACT AND SUCH
LAWS PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE COMMISSION, ANY
STATE SECURITIES COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED
THE MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THE MEMORANDUM. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL;

 

(y)          In
making an investment decision, investors must rely on their own examination of Company and the terms of the Offering, including
the merits and risks involved. Investors should be aware that they will be required to bear the financial risks of this investment
for an indefinite period of time;

 

    	7

    	 

    

 

(z)          (For
ERISA plans only) The fiduciary of the ERISA plan (the “Plan”) represents that such fiduciary has
been informed of and understands the Company’s investment objectives, policies and strategies, and that the decision to invest
“plan assets” (as such term is defined in ERISA) in the Company is consistent with the provisions of ERISA that require
diversification of plan assets and impose other fiduciary responsibilities. The Purchaser or Plan fiduciary (a) is responsible
for the decision to invest in the Company; (b) is independent of the Company and any of its affiliates; (c) is qualified to make
such investment decision; and (d) in making such decision, the Purchaser or Plan fiduciary has not relied on any advice or recommendation
of the Company or any of its affiliates; and

 

(aa)         The
Purchaser has read in its entirety the Memorandum and all exhibits thereto, including, but not limited to, all information relating
to the Company, and the Securities, and understands fully to its full satisfaction all information included in the Memorandum including,
but not limited to, the Section entitled “Risk Factors”.

 

6.          Representations
and Warranties of the Company. The representations and warranties contained in Section 3 of the Unit Purchase Agreement to
be entered into by the Company and the Purchasers shall be incorporated herein by reference and shall be deemed to be made under
this Subscription Agreement.

 

7.          Indemnification.
The Purchaser agrees to indemnify and hold harmless the Company, Laidlaw and each of their respective officers, directors,
managers, employees, agents, attorneys, control persons and affiliates from and against all losses, liabilities, claims, damages,
costs, fees and expenses whatsoever (including, but not limited to, any and all expenses incurred in investigating, preparing
or defending against any litigation commenced or threatened) based upon or arising out of any actual or alleged false acknowledgment,
representation or warranty, or misrepresentation or omission to state a material fact, or breach by the Purchaser of any covenant
or agreement made by the Purchaser herein or in any other document delivered in connection with this Subscription Agreement.

 

8.          Binding
Effect. This Subscription Agreement will survive the death or disability of the Purchaser and will be binding upon and inure
to the benefit of the parties and their heirs, executors, administrators, successors, legal representatives, and permitted assigns.
If the Purchaser is more than one person, the obligations of the Purchaser hereunder will be joint and several and the agreements,
representations, warranties and acknowledgments herein will be deemed to be made by and be binding upon each such person and such
person’s heirs, executors, administrators, successors, legal representatives and permitted assigns.

 

9.          Modification.
This Subscription Agreement will not be modified or waived except by an instrument in writing signed by the party against whom
any such modification or waiver is sought.

 

10.         Notices.
Any notice or other communication required or permitted to be given hereunder will be in writing and will be mailed by certified
mail, return receipt requested, or delivered by reputable overnight courier such as FedEx against receipt to the party to whom
it is to be given (a) if to the Company, at the address set forth in the Unit Purchase Agreement or (b) if to the Purchaser, at
the address set forth on the signature page hereof (or, in either case, to such other address as the party will have furnished
in writing in accordance with the provisions of this Section 10). Any notice or other communication given by certified mail will
be deemed given at the time of certification thereof, except for a notice changing a party’s address which will be deemed
given at the time of receipt thereof. Any notice or other communication given by overnight courier will be deemed given at the
time of delivery.

 

    	8

    	 

    

 

11.         Assignability.
This Subscription Agreement and the rights, interests and obligations hereunder are not transferable or assignable by the Purchaser
and the transfer or assignment of any of the Securities will be made only in accordance with all applicable laws.

 

12.         Applicable
Law.  This Subscription Agreement will be governed by and construed under the laws of the State of New York as applied to
agreements among New York residents entered into and to be performed entirely within New York. The parties hereto (1) agree that
any legal suit, action or proceeding arising out of or relating to this Subscription
Agreement will be instituted exclusively in New York State Supreme Court, County of New York, or in the United States District
Court for the Southern District of New York, (2) waive any objection which the parties may have now or hereafter to the venue
of any such suit, action or proceeding, and (3) irrevocably consent to the jurisdiction of the New York State Supreme Court, County
of New York, and the United States District Court for the Southern District of New York in any such suit, action or proceeding.
Each of the parties hereto further agrees to accept and acknowledge service of any and all process which may be served in any
such suit, action or proceeding in the New York State Supreme Court, County of New York, or in the United States District Court
for the Southern District of New York and agrees that service of process upon it mailed by certified mail to its address will
be deemed in every respect effective service of process upon it, in any such suit, action or proceeding. THE PARTIES HERETO AGREE
TO WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS SUBSCRIPTION
AGREEMENT OR ANY DOCUMENT OR AGREEMENT CONTEMPLATED HEREBY.

 

13.         Blue
Sky Qualification. The purchase of Securities pursuant to this Subscription Agreement is expressly conditioned upon the exemption
from qualification of the offer and sale of the Securities from applicable federal and state securities laws.

 

14.         Use
of Pronouns. All pronouns and any variations thereof used herein will be deemed to refer to the masculine, feminine, neuter,
singular or plural as the identity of the person or persons referred to may require.

 

15.         Confidentiality.
The Purchaser acknowledges and agrees that any information or data the Purchaser has acquired from or about the Company not otherwise
properly in the public domain, was received in confidence. The Purchaser agrees not to divulge, communicate or disclose, except
as may be required by law or for the performance of this Subscription Agreement, or use to the detriment of the Company or for
the benefit of any other person or persons, or misuse in any way, any confidential information of the Company, including any trade
or business secrets of the Company and any business materials that are treated by the Company as confidential or proprietary, including,
without limitation, confidential information obtained by or given to the Company about or belonging to third parties.

 

16.         Miscellaneous.

 

(a)          This
Subscription Agreement, together with the other Transaction Documents, constitute the entire agreement between the Purchaser and
the Company with respect to the subject matter hereof and supersede all prior oral or written agreements and understandings, if
any, relating to the subject matter hereof. The terms and provisions of this Subscription Agreement may be waived, or consent for
the departure therefrom granted, only by a written document executed by the party entitled to the benefits of such terms or provisions.

 

(b)          Each
of the Purchaser’s and the Company’s representations and warranties made in this Subscription Agreement will survive
the execution and delivery hereof and delivery of the Securities.

 

    	9

    	 

    

 

(c)          Each
of the parties hereto will pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or others
engaged by such party) in connection with this Subscription Agreement and the transactions contemplated hereby whether or not the
transactions contemplated hereby are consummated.

 

(d)          This
Subscription Agreement may be executed in one or more counterparts each of which will be deemed an original, but all of which will
together constitute one and the same instrument.

 

(e)          Each
provision of this Subscription Agreement will be considered separable and, if for any reason any provision or provisions hereof
are determined to be invalid or contrary to applicable law, such invalidity or illegality will not impair the operation of or affect
the remaining portions of this Subscription Agreement.

 

(f)          Paragraph
titles are for descriptive purposes only and will not control or alter the meaning of this Subscription Agreement as set forth
in the text.

 

17.         Signature
Page. It is hereby agreed by the parties hereto that the execution by the Purchaser of this Subscription Agreement, in the
place set forth hereinbelow, will be deemed and constitute the agreement by the Purchaser to be bound by all of the terms and conditions
hereof as well as by the Unit Purchase Agreement and each of the other Transaction Documents, and will be deemed and constitute
the execution by the Purchaser of all such Transaction Documents without requiring the Purchaser’s separate signature on
any of such Transaction Documents.

 

[Remainder of page intentionally left blank.]

 

    	10

    	 

    

 

ANTI-MONEY LAUNDERING REQUIREMENTS

 

	
        The USA PATRIOT Act

         
	 	What is money laundering?	 	How big is the problem and why is it important?
	 	 	 	 	 
	The USA PATRIOT Act is designed to detect, deter, and punish terrorists in the United States and abroad.  The Act imposes new anti-money laundering requirements on brokerage firms and financial institutions.  Since April 24, 2002 all brokerage firms have been required to have new, comprehensive anti-money laundering programs. To help you understand these efforts, we want to provide you with some information about money laundering and our steps to implement the USA PATRIOT Act.	 	Money laundering is the process of disguising illegally obtained money so that the funds appear to come from legitimate sources or activities.  Money laundering occurs in connection with a wide variety of crimes, including illegal arms sales, drug trafficking, robbery, fraud, racketeering, and terrorism.	 	The use of the U.S. financial system by criminals to facilitate terrorism or other crimes could well taint our financial markets.  According to the U.S. State Department, one recent estimate puts the amount of worldwide money laundering activity at $1 trillion a year.

 

	What are we required to do to eliminate money laundering?
	 	 
	Under new rules required by the USA PATRIOT Act, our anti-money laundering program must designate a special compliance officer, set up employee training, conduct independent audits, and establish policies and procedures to detect and report suspicious transaction and ensure compliance with the new laws.	As part of our required program, we may ask you to provide various identification documents or other information.  Until you provide the information or documents we need, we may not be able to effect any transactions for you.

 

    	11

    	 

    

 

PROTEA BIOSCIENCES GROUP,
INC.

SIGNATURE PAGE TO

SUBSCRIPTION AGREEMENT 

 

Purchaser hereby elects to purchase a total
of $_________________, representing ________ ______Unit(s), each Unit consisting of (i) 50,000 shares of Preferred Stock and (ii)
a Warrant to purchase 200,000 shares of Common Stock, at a purchase price of $100,000 per Unit (NOTE: to be completed by the Purchaser).

 

Date (NOTE: To be completed by the Purchaser):
__________________, 2014

 

	 
	If the Purchaser is an INDIVIDUAL, and if purchased as JOINT TENANTS, as TENANTS IN COMMON, or as COMMUNITY PROPERTY:

 

	 	 	 	 	 
	 	Print Name(s)	 	Social Security Number(s)	 
	 	 	 	 	 
	 	Print Name(s)	 	Social Security Number(s)	 
	 	 	 	 	 
	 	Signature(s) of Purchaser(s)	 	Signature	 
	 	 	 	 	 
	 	Address:	 	 	 
	 	 	 	 	 
	 	 	 	Date	 
	 	 	 	 	 

 

	 	 
	If the Purchaser is a PARTNERSHIP, CORPORATION, LIMITED LIABILITY COMPANY or TRUST:

 

	 	 	 	 	 
	 	 	 	Federal Taxpayer	 
	 	Name of Partnership,	 	Identification Number 	 
	 	Corporation, Limited	 	 	 
	 	Liability Company or Trust	 	 	 
	 	 	 	 	 
	 	By	 	 	 	 
	 	 	Name:	 	State of Organization	 
	 	 	Title:	 	 	 
	 	 	 	 	 
	 	Address:	 	 	 
	 	 	 	 	 
	 	 	 	Date	 
	 	 	 	 	 
	 	 	 	 	 	 

 

AGREED AND ACCEPTED:

 

PROTEA BIOSCIENCES GROUP, INC.

 

	By:	 	 	 	 
	 	Name:	 	Date	 
	 	Title:	 	 	 

 

    	 

    	 

    

 

Exhibit
A

 

FORM OF INVESTOR QUESTIONNAIRE

 

PROTEA BIOSCIENCES GROUP, INC.

 

For Individual Investors Only

 

(All individual investors must INITIAL
where appropriate. Where there are joint investors both parties must INITIAL):

 

	Initial _____	 	I certify that I have a “net worth” of at least $1 million either individually or through aggregating my individual holdings and those in which I have a joint, community property or other similar shared ownership interest with my spouse.  For purposes of calculating net worth under this paragraph, (i) the primary residence shall not be included as an asset, (ii) to the extent that the indebtedness that is secured by the primary residence is in excess of the fair market value of the primary residence, the excess amount shall be included as a liability, and (iii) if the amount of outstanding indebtedness that is secured by the primary residence exceeds the amount outstanding 60 days prior to the execution of this Subscription Agreement, other than as a result of the acquisition of the primary residence, the amount of such excess shall be included as a liability.
	 	 	 
	Initial _____	 	I certify that I have had an annual gross income for the past two years of at least $200,000 (or $300,000 jointly with my spouse) and expect my income (or joint income, as appropriate) to reach the same level in the current year.

 

For Non-Individual
Investors

 

(all Non-Individual
Investors must INITIAL where appropriate):

 

	Initial _____	 	The undersigned certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by persons who meet either of the criteria for Individual Investors, above.
	 	 	 
	Initial _____	 	The undersigned certifies that it is a partnership, corporation, limited liability company or business trust that has total assets of at least $5 million and was not formed for the purpose of investing in Company.
	 	 	 
	Initial _____	 	The undersigned certifies that it is an employee benefit plan whose investment decision is made by a plan fiduciary (as defined in ERISA §3(21)) that is a bank, savings and loan association, insurance company or registered investment adviser.
	 	 	 
	Initial _____	 	The undersigned certifies that it is an employee benefit plan whose total assets exceed $5,000,000 as of the date of the Subscription Agreement.
	 	 	 
	Initial _____	 	The undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons who meet either of the criteria for Individual Investors, above.

 

    	 

    	 

    

 

	Initial _____	 	The undersigned certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its individual or fiduciary capacity.
	 	 	 
	Initial _____	 	The undersigned certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange Act of 1934.
	 	 	 
	Initial _____	 	The undersigned certifies that it is an organization described in §501(c)(3) of the Internal Revenue Code with total assets exceeding $5,000,000 and not formed for the specific purpose of investing in Company.
	 	 	 
	Initial _____	 	The undersigned certifies that it is a trust with total assets of at least $5,000,000, not formed for the specific purpose of investing in Company, and whose purchase is directed by a person with such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment.
	 	 	 
	Initial _____	 	The undersigned certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or instrumentality thereof, for the benefit of its employees, and which has total assets in excess of $5,000,000.
	 	 	 
	Initial _____	 	The undersigned certifies that it is an insurance company as defined in §2(a)(13) of the Securities Act of 1933, as amended, or a registered investment company.

  

    	 

    	 

    

 

PROTEA BIOSCIENCES GROUP, INC.

Investor Questionnaire

(Must be completed by Purchaser)

 

Section A - Individual Purchaser
Information

 

	Purchaser Name(s): 
	 
	 
	Individual executing Profile or Trustee:
	 
	 
	Social Security Numbers / Federal I.D. Number:
	 

 

	Date of Birth:	 	Marital Status:	 	 

 

	Joint Party Date of Birth:______________________	 
	 	 
	Investment Experience (Years):_________________	 
	 	 
	Annual Income:______________________	 
	 	 
	Liquid Net Worth:________________	 
	 	 
	Net Worth:_________________	 

 

	Investment Objectives (circle one or more):	Long Term Capital Appreciation, Short Term Trading, Businessman’s Risk, Income, Safety of Principal, Tax Exempt Income or other

 

	Home Street Address: 
	 
	 
	Home City, State & Zip Code: 
	 

 

	Home Phone:	 	Home Fax:	 	 

 

	Home Email:	 	 

 

	Employer: 
	 

 

	Employer Street Address:
	 
	 
	Employer City, State & Zip Code:
	 

 

	Bus. Phone:	 	Bus. Fax:	 	 

 

	Bus. Email:	 	 

 

	Type of Business:
	 

 

	LAIDLAW Account Executive / Outside Broker/Dealer:
	 

 

	Please check
if you are a FINRA member or affiliate of a FINRA member firm:	

 

    	 

    	 

    

 

Section B – Entity Purchaser Information

 

	Purchaser Name(s):
	 
	 
	Authorized Individual executing Profile or Trustee:
	 
	 
	Social Security Numbers / Federal I.D. Number:
	 

 

	Investment Experience (Years):_____________	 
	 	 
	Annual Income:_______________	 
	 	 
	Net Worth:_______________	 

  

Was the Trust formed for the specific purpose of purchasing the
Units?

 

 ̈ Yes  ̈
No

 

	Principal Purpose (Trust)________________________________________	 
	 
	Type of Business:_______________________________________________________	 

 

	Investment Objectives (circle one or more):	Long Term Capital Appreciation, Short Term Trading, Businessman’s Risk, Income, Safety of Principal, Tax Exempt Income or other

 

	Street Address:
	 
	 
	City, State & Zip Code: 
	 

 

	Phone:	______________________	Fax: 	 	 

 

	Email:	 	 

 

	Laidlaw Account Executive / Outside Broker/Dealer:
	 	 

 

    	 

    	 

    

 

Section C – Form of Payment –
Check or Wire Transfer

 

		____	Check payable to “SIGNATURE BANK, AS ESCROW AGENT FOR PROTEA BIOSCIENCES GROUP,
INC.

 

		____	Wire funds from my outside account according to the “To subscribe for Units of Preferred
Stock and Warrants to Purchase Shares of Common Stock in the private offering of PROTEA BIOSCIENCES GROUP, INC.”

 

____Wire funds from my LAIDLAW Account
– See following page

 

		____	The funds for this investment are rolled over, tax deferred from ____________________ within the
Allowed 60-day window

 

Section D – Purchaser Instructions
for Payments of any Dividends

 

		 ̈	Please make any dividend and any other payment checks pursuant to the Units to “Sterne Agee & Leach Inc. c/f ____________________[Insert
Client Name]” and deliver such checks to Laidlaw so that they may deposit them into my Laidlaw brokerage account

 

		 ̈	Please make out any dividend and any other payment checks pursuant to the Units in the registered name of the Purchaser set
forth in the signature page to the Subscription Agreement for the Units and mail such checks to me at the address specified in
such signature page.

 

Section E – Securities Delivery
Instructions (check one)

 

____ Please deliver my securities to Laidlaw for deposit into my
brokerage account.

 

____ Please deliver my securities to the address listed in the above
Investor Questionnaire.

 

____ Please deliver my securities to the below address:

______________________________________

______________________________________

______________________________________

______________________________________

 

Purchaser Signature(s) _______________________________________     Date_______________

 

    	 

    	 

    

 

Wire Transfer Authorization

 

	 	TO:	OPERATIONS MANAGER
	 	 	LAIDLAW & CO. (UK) LTD.
	 	 	 
	 	RE:	Client Wire Transfer Authorization
	 	 	PROTEA BIOSCIENCES GROUP, INC.

 

DATE:________________

 

 

 

This memorandum authorizes the transfer of the following
listed funds from my LAIDLAW Brokerage Account as follows:

 

LAIDLAW Brokerage Account # ______________________

 

Wire Amount                                  $______________________

 

SIGNATURE BANK

261 Madison Avenue

New York, NY 10016

 

ABA Number: 026013576

For Credit to
Signature Bank, as Escrow Agent for

Protea Biosciences
Group, Inc.

Account No.:
1502351989

 

	 	REFERENCE:
	 	 
	 	PURCHASER'S LEGAL NAME
	 	 	 
	 	 
	 	TAX ID NUMBER
	 	 	 
	 	 
	 	PURCHASER'S ADDRESS
	 	 	 

 

FBO: ________________________________________________

 

	Signature:	 	 
	 	 
	Signature:	 	 
	 	(Joint Signature)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]